Trials / NCT04919473
Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Optogenetics, Gene therapy
- Sponsor
- Nanoscope Therapeutics Inc.
- Treatment
- Gene Therapy product:vMCO-I
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa, Retinal Diseases, Retinal Degeneration
- Ages
- 18 Years to no upper limit
- Enrollment
- 11 participants
- Started
- 2019-10-23
- Main results expected
- 2020-02-25
- Results posted
- Not yet
- Record last updated
- 2021-06-09
What the study is testing
The purpose of the study is to evaluate the safety and tolerability of a single intravitreal injection of virally-carried Multi-Characteristic Opsin I (vMCO-I)
Where it runs
India (1)
- JPM Rotary Club of Cuttack Eye Hospital and Research Institute, Cuttack, Odisha